Immunotherapy

Overview

Immunotherapy is a type of treatment that boosts your body's natural defenses to help fight cancer.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified GSK2857916
GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified PVX-410
PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

Verified RO6870810
RO6870810

RO6870810 is a BET inhibitor that is openly enrolling in a dose expansion clinical trial around the US.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified SGN-CD48A
SGN-CD48A

SGN-CD48A is an antibody-drug conjugate (ADC) directed against the CD48 protein.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified GSK2857916
GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified SGN-CD48A
SGN-CD48A

SGN-CD48A is an antibody-drug conjugate (ADC) directed against the CD48 protein.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified CAR2 Anti-CD38 A2 CAR-T Cells
CAR2 Anti-CD38 A2 CAR-T Cells

CAR2 Anti-CD38 A2 CAR-T Cells have the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified GSK2857916
GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified RO6870810
RO6870810

RO6870810 is a BET inhibitor that is openly enrolling in a dose expansion clinical trial around the US.

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified SGN-CD48A
SGN-CD48A

SGN-CD48A is an antibody-drug conjugate (ADC) directed against the CD48 protein.

Verified TAK-079
TAK-079

TAK-079 is a monoclonal antibody with a low-volume subcutaneous injection that targets the CD38 protein.

Verified Tinostamustine
Tinostamustine

Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Verified Nivolumab
Nivolumab

Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.

Verified PVX-410
PVX-410

PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Resources

There are no resources, links or videos to display for this tag.